Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05853367 · ClinicalTrials.gov registry record · Phase 1
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
A Phase 1 study of Advanced Solid Tumors and Metastatic Solid Tumors, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 178
- Enrollment target
- 20
- Study locations
NCT05853367: Recruiting Phase 1 study of Advanced Solid Tumors and Metastatic Solid Tumors, sponsored by Merck Sharp & Dohme.
NCT05853367 is a Phase 1 study of Advanced Solid Tumors and Metastatic Solid Tumors that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 178 participants, below the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05853367, a Phase 1 study of Advanced Solid Tumors and Metastatic Solid Tumors, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 178 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.
Primary Outcome
DLT will be defined as any drug-related AE observed during the DLT evaluation period (e.g. Cycle 1) that results in a change to a given dose or a delay in initiating the next cycle.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG MK-1084
- DRUG MK-0472
Study Locations (20)
Other
- Rambam Health Care Campus ( Site 0304) - Haifa
- Shaare Zedek Medical Center ( Site 0303) - Jerusalem
- Rabin Medical Center ( Site 0301) - Petah Tikva
- Sheba Medical Center ( Site 0300) - Ramat Gan
- Sourasky Medical Center ( Site 0302) - Tel Aviv
Region M. de Santiago
- Centro de Estudios Clínicos SAGA ( Site 0701) - Santiago
- Fundacion Arturo Lopez Perez ( Site 0700) - Santiago
- Centro de Investigacion Clinicadela Universidad Catolica ( Site 0703) - Santiago
- Bradfordhill ( Site 0702) - Santiago
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001) - Hackensack
- Rutgers Cancer Institute of New Jersey ( Site 0005) - New Brunswick
Quebec
- Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0100) - Montreal
- Jewish General Hospital ( Site 0104) - Montreal
Illinois
- Northwestern Memorial Hospital ( Site 0002) - Chicago
Kentucky
- The University of Louisville, James Graham Brown Cancer Center ( Site 0004) - Louisville
Ontario
- Princess Margaret Cancer Centre ( Site 0101) - Toronto
Masovian Voivodeship
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0401) - Warsaw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2028-02-12 |
| Phase | Phase 1 |
What NCT05853367 shows while recruiting
NCT05853367 is an interventional study that assigns participants to a tested intervention. The registered 178 participants enrollment target is mid-sized for trials with a published cap, below the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (10% lower).
The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05853367 names 20 study sites across 11 states, led by Other, Region M. de Santiago, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05853367 about?
NCT05853367 is a clinical study titled "Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)". The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.
What is the current status of trial NCT05853367?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 178 participants. The study started on 2023-07-06. Estimated completion is 2028-02-12.
What conditions does trial NCT05853367 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Metastatic Solid Tumors.
What interventions are being tested in trial NCT05853367?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), MK-1084 (DRUG), MK-0472 (DRUG).
Who is sponsoring clinical trial NCT05853367?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05853367 being conducted?
This trial has 20 study locations across Illinois, Kentucky, New Jersey, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05853367's enrollment target sits among peer trials
178 48th of 144 higher than 96 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03642002 · 178 participants · NA
The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU
- NCT04227847 · 178 participants · Phase 1
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
- NCT04855214 · 178 participants
Evaluating the Experience of Upper Limb Prosthesis Use
- NCT05391126 · 178 participants · NA
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI